This laboratory has previously demonstrated that there is an opiate receptor-mediated, concentrationdependent modulation of the electrically stimulated release of enkephalin from the guinea pig myenteric plexus. Low doses of opioids (nanomolar) enhance release, whereas higher concentrations (10-100 nM) inhibit release. We now demonstrate that the in vivo i.p. administration of the islet-activating protein from pertussis toxin (PTX; 50 jtg/500 g of body weight) markedly diminishes the potency of jA, 6, or K-selective opioids to inhibit the evoked release of enkephalin. In contrast, PTX is without effect on the enhancement of enkephalin release observed after treatment with nanomolar concentrations of the above opioids. Conversely, pretreatment with cholera toxin (CTX; 0.01 nM for 3 hr in vitro) has no effect on the , 6, or K opioid inhibition of evoked enkephalin release but abolishes the ability of nanomolar concentrations of these agonists to enhance stimulated enkephalin release. These data indicate that different classes of guanine nucleotide-binding proteins (G proteins) appear to mediate the opioid enhancement or inhibition of stimulated enkephalin release. Furthermore, they suggest that a PTX-sensitive G protein (G1 or Go) and a CTX-sensitive G protein (Gs) are integral components of the mechanism that mediates opioid inhibition and opioid enhancement, respectively, of evoked enkephalin release. To our knowledge, this report represents the first demonstration that Gs-coupled opiate receptors (in addition to those that are coupled to G.) can modulate transmitter release.
positive and negative feedback. ,u-, 6-, or K-selective opioids (10- 100 nM) inhibit the electrically evoked release of [Met5] enkephalin from the guinea pig myenteric plexus (1) . This is consistent with the prevailing view that the predominant action of opioid peptides is inhibitory, hyperpolarizing neural elements throughout the central nervous system. At lower concentrations of opioid, however, the opposite effect is observed. Pretreatment with nanomolar concentrations of opiate receptor type-selective agonists results in an enhancement of the stimulated release of [Met5] enkephalin. Both the opioid excitatory and inhibitory effects are antagonized by naloxone (1) .
A variety of data are consistent with the involvement of the adenylyl cyclase/cAMP second messenger system in mediating the opioid enhancement or inhibition of the evoked release of [Met5] enkephalin. For example, elevating intracellular levels of cAMP or activating cAMP-dependent processes results in a 2-fold increase in the electrically stimulated release of [Met5] enkephalin (1) . This suggests that this second messenger system could modulate stimulationinduced release of enkephalin. Thus, the enhancement of release observed following pretreatment with nanomolar concentrations of opioid could result from activation of the cAMP second messenger system. Furthermore, opioids are no longer able to inhibit the evoked release of [Met5]-enkephalin in preparations in which cAMP levels have been elevated or cAMP-dependent processes have been activated (1) . This suggests that opioid suppression of the evoked release of [Met5lenkephalin could result from the ability of the opioids to inhibit the cAMP second messenger system.
Guanine nucleotide-binding proteins (G proteins) are essential components of receptor-mediated regulation of adenylyl cyclase (2) (3) (4) (5) (6) . The direction of this regulation depends on the nature ofthe G protein to which the receptor is coupled (3) (4) (5) (6) . Receptors associated with G, inhibit, whereas those associated with Gs stimulate, adenylyl cyclase activity. Pertussis toxin (PTX) (3-7) or cholera toxin (CTX) (8) catalyze the ADP-ribosylation of the a subunit of G proteins and thereby interfere with their function. For example, PTX stabilizes Gi in an inactive state, blocking its coupling with receptors. The action of CTX results in an inhibition of GTPase activity associated with Gs (9) , increased adenylate cyclase activity (8) , and decreased sensitivity of the highaffinity agonist-receptor complex to the regulatory effects of guanine nucleotides (10) . Each, however, has a different substrate specificity. PTX ADP-ribosylates G, and Go but not Gs, whereas CTX ADP-ribosylates Gs but not G1 or Go.
Therefore, these toxins were used to test the hypothesis that different G proteins were essential for the opioid enhancement or inhibition of stimulated enkephalin release.
MATERIALS AND METHODS
"Strips" of guinea pig longitudinal mus'cle with adherent myenteric plexus (LMMP) were prepared, mounted, and superfused in a stimulating chamber, as described (1, (11) (12) (13) . The Krebs solution used to superfuse the tissue contained captopril (10 mM), thiorphan (0.3 mM), bestatin (10 mM), and L-leucyl-L-leucine (2 mM) to protect against the action of proteases (14) . The superfusion rate was maintained at 1 ml/min. Fractions (0.5 ml) were collected on ice and oxidized immediately with hydrogen peroxide (0.3% at 40C overnight) after which each sample was aliquoted in duplicate (100 pl each) and lyophilized to dryness. The protease inhibitors mentioned above were present during the 30-min equilibration period before the start of each experiment and thereafter for its duration. Sufentanil citrate (SFNC; Janssen), [2-D- Abbreviations: G protein, guanine nucleotide-binding protein; Gs, Gi, and Go, stimulatory, inhibitory, and "unknown" G proteins; CTX, cholera toxin; PTX, pertussis toxin; LMMP, longitudinal muscle with adherent myenteric plexus; SFNC, sufentanil citrate;
benzeneacetamide. *To whom reprint requests should be addressed.
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Physiology/Pharmacology: Gintzler and Xu penicillamine,5-D-penicillamine]enkephalin (DPDPE), and dynorphin A-(1-13) {or 3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide (U50,488H); Upjohn} were used as IL-, 6-, and K-selective agonists, respectively (15, 16) . It seems unlikely that dynorphin A-(1-13) is being degraded with the generation of shorter, less-selective dynorphin A fragments because the LMMP preparation is continuously superfused with drug (each dynorphin A molecule is in contact with the tissue for only 30 sec). Moreover, the preparation is bathed with several peptidase inhibitors that provide at least partial protection from degradation after longer periods of incubation with myenteric plexus preparations. Enkephalin-like immunoreactivity was determined by using an RIA procedure as described (1) . A standard curve (3.12, 6.25, 12.5, 25, 50, 100, 250, 500, and 1000 pg per assay tube) in which the percentage of inhibition of binding was plotted against the logarithm of unlabeled oxidized enkephalin in the reaction tube was generated in each experiment. The minimum detectable concentration was 3 pg, at which t20% inhibition of binding was observed. Cross-reactivity with [5- In vivo treatment with PTX was performed as described (17, 18) . Briefly, 50 ,ug of PTX was dissolved in 0.5 ml of saline. Guinea pigs weighing 450-500 g were injected i.p. with PTX (50 Ag/500 g). After 6 days, LMMP strips were prepared as described above. The ability of opioids to modulate (enhance or inhibit) enkephalin release in PTX-treated tissue was determined and compared with that observed in untreated tissue.
One milligram of whole CTX (subunit A and subunit B; azide-free) or its B subunit (CTX B; choleragenoid) was dissolved in 100 ml of Krebs buffer (120 nM). The guinea pig gut was incubated with CTX (A + B subunits) or CTX B (120 or 0.01 nM) in vitro for a minimum of 3 hr prior to the start of each experiment. The LMMP strips were prepared as described above, and the evoked release of enkephalin was determined before, during, and after pretreatment with either an excitatory or inhibitory concentration of opioid. The percent enhancement (or inhibition) of release in CTX (A + B subunits)-or CTX B-treated tissue was compared with the magnitude of change observed in untreated tissue.
The opioid responsiveness of naive and toxin-treated tissue was compared by using a two-way analysis of variance. The effect of whole CTX (A + B subunits; 0.01 nM) on the opioid enhancement of stimulated enkephalin release was compared with that of CTX B (0.01 nM) by using a one-way analysis of variance and a Scheffe multiple range test. P In contrast to that observed in PTX-treated preparations, the ability of opioids to enhance stimulated enkephalin release was abolished in ilea treated with CTX (Fig. 3 ). This effect was selective for opioid excitatory actions. Inhibitory responses to SFNC or U50,488H were not affected by identical treatment with CTX (Fig. 4) treated (120 nM) preparations. This, however, was not observed in tissue that had been treated with an =10,000-fold lower concentration of CTX (Fig. 4) , despite the fact that this treatment was sufficient to abolish opioid excitatory responses (see Fig. 5 ). These data suggest that the opioid enhancement of stimulated [Met5Jenkephalin release requires a CTX-sensitive G protein that is not involved with the process(es) that mediates the opioid inhibition of this opioid peptide. Fig. 3 except that inhibitory concentrations of SFNC, DPDPE, and U50,488H were used. n = 5, 6, and 6 for SFNC, DPDPE, and 450,488H, respectively. *, P < 0.05.
[Mete]Enkephalin Release. When the effect on enkephalin release of a sufficiently dilute (0.01 nM), equimolar concentration of either the whole toxin or its B subunit was determined, only the whole toxin had activity (Fig. 5) . The B subunit by itself, at these concentrations, was without effect on excitatory opioid responsiveness. This strongly suggests that ADP-ribosylation of Gs (the activity for which resides in the A subunit) is sufficient to abolish opioid excitatory responses. DISCUSSION PTX and CTX ADP-ribosylate G proteins and thereby interfere with their function (7, 8, 19) . They are therefore excellent tools with which to probe the possible involvement of G proteins in the opioid modulation of enkephalin release. Although the G protein specificity of these toxins is not absolute (PTX ADP-ribosylates Gi and GO), the substrate specificity of PTX and CTX differ. Therefore, a comparison of the effects of each toxin on opioid responsiveness can be used to differentiate between the involvement of different G proteins in the opioid excitation or inhibition of enkephalin release.
PTX and CTX each contain two subunits (19) (20) (21) (22) (23) . The A subunit of each contains the ADP-ribosylating activity that inactivates G proteins (19, 21, 23, 24) . The B unit binds to membrane gangliosides and facilitates cellular penetration of the A subunit (25, 26) . The attenuation by PTX and CTX of opioid inhibitory and excitatory modulation, respectively, of enkephalin release could be due to the activity of either component. Highly dilute (0.01 nM) concentrations of whole CTX retain the ability to abolish opioid enhancement of stimulated enkephalin release, whereas an equimolar concentration of its B subunit has no effect. Thus, the ADPribosylation of a G protein is the most likely explanation for the effect of this toxin on the opiate receptor-mediated enhancement of [Met5]enkephalin release.
Treatment with CTX has been associated with inhibition of G-protein-associated GTPase activity and elevated levels of cAMP (8, 9) . Elevation of cAMP content, however, by forskolin or stimulation of cAMP-dependent processes by 8-(4-chlorphenylthio)-cAMP does not alter the ability of nanomolar concentrations of opioid to enhance the evoked release of [Met5]enkephalin (1) . Thus, it is unlikely that any CTX-induced elevation in cAMP is responsible for its ability to block the opioid enhancement ofenkephalin release. These considerations suggest that the attenuation of opioid enhancement of evoked enkephalin release by CTX is most likely due to a decrease in the efficacy of opioid ligand activation of G-protein-coupled opiate receptors. This would be in agreement with a previous report demonstrating that treatment with CTX does not substantially alter the guanine nucleotide activation of adenylyl cyclase but decreases by 10-fold the nucleotide modulation of 13-adrenergic receptor affinity for agonists (10) . These data strongly suggest that a G protein mediates the enhancement of evoked enkephalin release that is produced by low concentrations of opioid. Additionally, the ability of PTX to abolish opioid inhibition of enkephalin release suggests that a G protein is an intermediate in this effect as well. The selectivity of the effect of each toxin-i.e., the inability of PTX and CTX to block opioid excitatory and inhibitory responses, respectively-clearly differentiates the G protein that is associated with each opioid effect.
The biochemical identity ofthe pertinent G proteins remains ambiguous. It is, however, tempting to conjecture the association of a G protein structurally related to G. and Go with opiate excitatory and inhibitory modulation of enkephalin release, respectively. To our knowledge, this is the first demonstration that opiate receptors coupled to G. (in addition to those that are coupled to GO) can modulate neurotransmitter release. It should be noted that the failure of PTX and CTX to alter the stimulated release of [MetJenkephalin in the absence of an opioid agonist could suggest that neither of these G proteins is an essential intermediate in the process(es) that couples enkephalin release with neuronal depolarization. Additionally, the failure of CTX or PTX to alter evoked release could be due to the superfusion technique employed, which does not allow released enkephalin to remain in contact with the myenteric plexus. Thus, the self-regulatory role of endogenous opioids on endogenous opioid systems is not manifest under the current experimental conditions. G proteins have been shown to mediate inhibition of voltage-dependent calcium channels by neurotransmitters (27) . Thus, via this mode of action, they could be important intermediaries in the processes governing the well-known action of opioids to suppress calcium currents and thereby inhibit the release of neurotransmitters. In this regard it is relevant to note that PTX has also been shown to abolish the opioid inhibition of evoked acetylcholine release from the myenteric plexus (17, 18) . Additionally, the intracerebroventricular pretreatment of rats with PTX decreases the antinoceceptive effect of morphine (regardless of the route of administration; ref. 28) , and the application of toxin to the intrathecal space attenuates the analgesia produced by the (29) .
The ability of CTX to abolish opioid enhancement of enkephalin release suggests a dual role for G proteins in regulating the release of [Met5Jenkephalin; they can act as intermediaries in the enhancement (as well as inhibition) of the release of this opioid peptide. This action could result from a G-protein-mediated prolongation of calcium currents.
Electrophysiological observations parallel these results and support this hypothesis. In several preparations, low concentrations of morphine or opioid peptides have been shown to prolong, whereas higher concentrations shorten, the duration of calcium currents (30) (31) (32) . Moreover, in dorsal root ganglia spinal cord explant cultures, the opioid excitatory and inhibitory modulation of calcium currents can be blocked by treatment with CTX and PTX, respectively (33, 34 (1991) 4745 has been well documented. Activation of adenylyl cyclase and subsequent cAMP-dependent phosphorylation of a protein that is part of or close to the calcium channel has been shown to alter its activity (35) (36) (37) and could underlie the positive or negative opioid modulation of enkephalin release. Alternatively, direct modulation of ion channels by G proteins must be considered. For example, activated G, or its a subunit has been shown to directly regulate mammalian cardiac calcium channels in membrane patches obtained from guinea pig cardiac myocytes and bovine cardiac sarcolemmal vesicles incorporated into planar lipid bilayers (38, 39) . G proteins have also been shown to directly regulate a subset of potassium channels (40) . More recently it has been demonstrated that G-protein modulation of adenylyl cyclase and ion channels can be activated concomitantly in response to a single agonist (41) . For example, the P-adrenergic receptor agonist isoproterenol has been shown to activate Gs, which enhances calcium currents (and sodium currents) by both an indirect cytoplasmic process (adenylyl cyclase) and a direct, membrane-delimited pathway (direct ion channel modulation). Both modes of action could be relevant to the bimodal opioid regulation of enkephalin release.
Thus far, it has not been possible to pharmacologically distinguish between those opiate receptors that mediate the enhancement or inhibition of stimulated [Met5]enkephalin release. The existence of distinct "excitatory" and "inhibitory" opiate receptors remains an open question. Differential regulation of adenylyl cyclase by different types ofa common receptor is not unprecedented. Inhibition and stimulation of adenylyl cyclase by a2-adrenergic and f-adrenergic receptors, respectively, is well documented (3, 5, 42) and could serve as a useful model for the opiate receptor-mediated regulation of enkephalin release. Alternatively, the same opiate receptor could be coupled to two different effectors as has been shown for the M2 type of muscarinic receptor (43) . Recombinant M2-muscarinic receptors expressed in cells lacking endogenous receptor both inhibit adenylyl cyclase and stimulate inositol phospholipid hydrolysis. Both effects require a G protein, as indicated by their inhibition by PTX. The stimulation of inositol phospholipid hydrolysis, however, is much less efficient and more dependent on receptor levels than the inhibition of adenylyl cyclase. In an analogous fashion, the dependence on concentration of the direction of the opioid regulation of enkephalin release could also be due to differences in the efficiency of coupling of the opiate receptor to the G protein that mediates enhancement or inhibition of enkephalin release. Alternatively, the concentration dependence of the opioid bimodal modulation of enkephalin release could also be due to the coupling of highand low-affinity opiate receptors to different G proteins.
In summary, the evoked release of enkephalin from myenteric neurons is regulated by positive and negative feedback mechanisms. Different signal transducers (G proteins) appear to mediate the opioid enhancement or inhibition of stimulated [Met5]enkephalin release. The interrelationship between the pathway mediating opioid enhancement or inhibition of enkephalin release and the factors that influence the relative responsiveness to each may be of considerable significance to understanding acute and long-term effects of narcotics.
